{"product_id":"global-cell-line-development-for-biologics-market-growth-status-and-outlook-2023-2029","title":"Global Cell Line Development for Biologics Market Growth (Status and Outlook) 2023-2029","description":"\u003cp\u003eGlobal Cell Line Development for Biologics Market Growth (Status and Outlook) 2023-2029\u003cbr\u003e\nThe global Cell Line Development for Biologics market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.\u003c\/p\u003e\n\n\u003cp\u003eUnited States market for Cell Line Development for Biologics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.\u003c\/p\u003e\n\n\u003cp\u003eChina market for Cell Line Development for Biologics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.\u003c\/p\u003e\n\n\u003cp\u003eEurope market for Cell Line Development for Biologics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.\u003c\/p\u003e\n\n\u003cp\u003eGlobal key Cell Line Development for Biologics players cover Lonza, Corning, Sartorius, Thermo Fisher Scientific, Selexis, Beckman Coulter (Danaher ), CYTENA, Molecular Devices and Samsung Biologics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.\u003c\/p\u003e\n\n\u003cp\u003eCell line development is a critical step in the production of biologics. Biologics are complex molecules that are produced by living cells, such as proteins, antibodies, and vaccines. To produce biologics in large quantities, scientists need to develop cell lines that can produce these molecules consistently and at high levels.\u003c\/p\u003e\n\n\u003cp\u003eLPI (LP Information)' newest research report, the “Cell Line Development for Biologics Industry Forecast” looks at past sales and reviews total world Cell Line Development for Biologics sales in 2022, providing a comprehensive analysis by region and market sector of projected Cell Line Development for Biologics sales for 2023 through 2029. With Cell Line Development for Biologics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cell Line Development for Biologics industry.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report provides a comprehensive analysis of the global Cell Line Development for Biologics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M\u0026amp;A activity. This report also analyzes the strategies of leading global companies with a focus on Cell Line Development for Biologics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cell Line Development for Biologics market.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cell Line Development for Biologics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cell Line Development for Biologics.\u003c\/p\u003e\n\n\u003cp\u003eThis report presents a comprehensive overview, market shares, and growth opportunities of Cell Line Development for Biologics market by product type, application, key players and key regions and countries.\u003c\/p\u003e\n\n\u003cp\u003eMarket Segmentation:\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by type\u003cbr\u003e\nCHO Cell Lines\u003cbr\u003e\nHEK293 Cell Lines\u003cbr\u003e\nInsect Cell Lines\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by application\u003cbr\u003e\nMonoclonal Antibodies\u003cbr\u003e\nRecombinant Proteins\u003cbr\u003e\nVaccines\u003c\/p\u003e\n\n\u003cp\u003eThis report also splits the market by region:\u003cbr\u003e\nAmericas\u003cbr\u003e\nUnited States\u003cbr\u003e\nCanada\u003cbr\u003e\nMexico\u003cbr\u003e\nBrazil\u003cbr\u003e\nAPAC\u003cbr\u003e\nChina\u003cbr\u003e\nJapan\u003cbr\u003e\nKorea\u003cbr\u003e\nSoutheast Asia\u003cbr\u003e\nIndia\u003cbr\u003e\nAustralia\u003cbr\u003e\nEurope\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nUK\u003cbr\u003e\nItaly\u003cbr\u003e\nRussia\u003cbr\u003e\nMiddle East \u0026amp; Africa\u003cbr\u003e\nEgypt\u003cbr\u003e\nSouth Africa\u003cbr\u003e\nIsrael\u003cbr\u003e\nTurkey\u003cbr\u003e\nGCC Countries\u003c\/p\u003e\n\n\u003cp\u003eThe below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.\u003cbr\u003e\nLonza\u003cbr\u003e\nCorning\u003cbr\u003e\nSartorius\u003cbr\u003e\nThermo Fisher Scientific\u003cbr\u003e\nSelexis\u003cbr\u003e\nBeckman Coulter (Danaher )\u003cbr\u003e\nCYTENA\u003cbr\u003e\nMolecular Devices\u003cbr\u003e\nSamsung Biologics\u003cbr\u003e\nHera BioLabs\u003cbr\u003e\nGTP Bioways\u003cbr\u003e\nAbzena\u003cbr\u003e\nFyoniBio\u003cbr\u003e\nCatalent\u003cbr\u003e\nWuXi Biologics\u003c\/p\u003e\n\n\u003cp\u003ePlease note: The report will take approximately 2 business days to prepare and deliver.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"May, 2023 \/ 113 Pages \/ MCW16230089","offer_id":47647039848754,"sku":null,"price":4392.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-cell-line-development-for-biologics-market-growth-status-and-outlook-2023-2029","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}